Summary of Significant Accounting Policies (Details) - USD ($) |
3 Months Ended | |
|---|---|---|
Mar. 31, 2026 |
Mar. 31, 2025 |
|
| Summary of Significant Accounting Policies (Details) [Line Items] | ||
| Upfront fee (in Dollars) | $ 10,000 | |
| Research and development costs (in Dollars) | $ 103,533 | $ 5,282 |
| Convertible Debt [Member] | ||
| Summary of Significant Accounting Policies (Details) [Line Items] | ||
| Shares issuable upon conversion of notes | 14,131,738 | |
| Common Stock Warrants [Member] | ||
| Summary of Significant Accounting Policies (Details) [Line Items] | ||
| Shares issuable upon exercise of warrants | 37,556 | 40,767 |
| Series A Preferred Stock [Member] | ||
| Summary of Significant Accounting Policies (Details) [Line Items] | ||
| Shares issuable upon the conversion | 3,286,256 | |
| Shares issuable upon conversion of notes | 3,298,159 | |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Cash received for fees during the current period. This element excludes cash proceeds from license fees. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|